More than 200,000 men develop potentially deadly prostate cancer each year, according to the Centers for Disease Control and Prevention. There is mounting evidence to support the idea that low levels of testosterone may be connected with a potential raise in prostate cancer.
For several decades it has been assumed that higher testosterone leads to a greater growth of benign and malignant prostate tissue, but this view has come under greater scrutiny over the last several years. Numerous small in-cli
nic trials and population-based studies fail to support the historically held idea that testosterone therapy poses an increased risk.
Current evidence strongly supports that testosterone replacement therapy is
safe for the prostate. Maintaining a normal range of testosterone has greater potential to reduce the risk of prostate cancer.
Regular testosterone testing is particularly important for men on testosterone replacement therapy to assure that levels stay within the acceptable testosterone range.